Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SFDA Grants Green Channel Approval to Market Drug without China Trials

publication date: Jul 24, 2009

Xian-Janssen, a division of Johnson & Johnson, has launched a new drug in China. Dacogen (decitabine), a novel treatment for myelodysplastic syndrome (MDS), received SFDA approval through the Green Channel, an expedited approval process that the SFDA introduced in January 2009. In Dacogen’s case, the SFDA allowed Xian-Janssen to begin marketing the drug in China based on trials done ex-China. More details...

Stock Symbol: (NYSE: JNJ)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here